文献速递基础与转化研究新药、器械与细胞基因治疗研发

血友病治疗格局变迁:从标准半衰期凝血因子到基因编辑

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
PubMed 文献 · Lancet · 2021-01-15

先天性血友病A和B为X连锁出血性疾病,替代治疗是基石但频繁静脉注射负担重、依从性差且部分患者出现抑制剂。生物工程凝血因子可减轻治疗负担,皮下注射新分子(如emicizumab或靶向抗凝血酶、TFPI、活化蛋白C)在有无抑制剂时均有效预防出血。基因治疗作为最终实现表型治愈的手段正处于晚期临床研究阶段。

要点

  • 替代治疗是血友病管理基石,但频繁静脉注射负担重且抑制剂影响预防效果。
  • 皮下注射新分子(如emicizumab或靶向天然抗凝物)可在有无抑制剂时有效预防出血。
  • 基因治疗旨在实现表型治愈,目前处于晚期临床研究阶段。

核心结论

  • 血友病治疗正从标准半衰期凝血因子替代向生物工程因子、皮下非因子疗法及基因治疗演变。

研究设计与样本

  • 本文为综述,聚焦先天性血友病A和B治疗格局的变化。

主要发现

  • 频繁静脉注射替代治疗负担重、成本高,导致依从性差和全球许多患者治疗可及性受限。
  • 生物工程凝血因子具有改善的药代动力学特征,可减轻治疗负担。
  • 替代治疗存在抑制剂开发风险,对出血预防和结局产生不利影响。
  • 皮下递送的新分子可在有或无抑制剂时提供有效预防,机制为替代凝血因子促凝功能(如emicizumab)或靶向天然抗凝物(抗凝血酶、组织因子途径抑制物或活化蛋白C)。

临床怎么用

  • 临床可考虑生物工程凝血因子以减轻治疗负担,但需警惕抑制剂风险。
  • 皮下非因子疗法(如emicizumab或靶向天然抗凝物)可在有或无抑制剂时用于出血预防。
  • 基因治疗作为潜在表型治愈手段,目前仍处于晚期临床研究阶段,尚未进入常规实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chronic crippling arthropathy. Frequent intravenous injections are burdensome and costly for patients, consequently with poor adherence and restricted access to therapy for many patients worldwide. Bioengineered clotting factors with enhanced pharmacokinetic profiles can reduce the burden of treatment. However, replacement therapy is associated with a risk for inhibitor development that adversely affects bleeding prevention and outcomes. Novel molecules that are subcutaneously delivered provide effective prophylaxis in the presence or absence of inhibitors, either substituting for the procoagulant function of clotting factors (eg, emicizumab) or targeting the natural inhibitors of coagulation (ie, antithrombin, tissue factor pathway inhibitor, or activated protein C). The ultimate goal of haemophilia treatment would be a phenotypical cure achievable with gene therapy, currently under late phase clinical investigation.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Mancuso ME, Mahlangu JN, Pipe SW, et al. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021. PMID: 33460559. doi:10.1016/S0140-6736(20)32722-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。